Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard M Stone

Showing results (41-50 of 420) with videos related to

Pageof 42
Sort By:
Current Hematologic Malignancy Reports|April 29, 2010
New agents for the treatment of patients with acute lymphoblastic leukemiaDaniel J DeAngelo, Richard M Stone
Blood|October 3, 2009
Screens, iron, and leukemiaRichard M Stone, Daniel J DeAngelo
Hematology/Oncology Clinics of North America|July 5, 2017
The Development of FLT3 Inhibitors in Acute Myeloid LeukemiaJacqueline S Garcia, Richard M Stone
Journal of Oncology Practice|August 11, 2017
Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice?Marlise R Luskin, Richard M Stone
Hematology/Oncology Clinics of North America|April 3, 2010
Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromesDavid P Steensma, Richard M Stone
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed diseaseL Andres Sirulnik, Richard M Stone
Blood Advances|January 28, 2025
Things (like AML salvage) go better with VEN(etoclax)Eric S Winer, Richard M Stone
Current Opinion in Oncology|January 16, 2002
The challenge of acute myeloid leukemia in older patientsMikkael A Sekeres, Richard M Stone
Therapeutic Advances in Hematology|July 20, 2019
Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approachesEric S Winer, Richard M Stone
Blood|July 23, 2011
Lenalidomide in AML: del(5q) or who?David P Steensma, Richard M Stone
Pageof 42

Showing results (41-50 of 420) with videos related to

Sort By:
Pageof 42
Current Hematologic Malignancy Reports|April 29, 2010
New agents for the treatment of patients with acute lymphoblastic leukemiaDaniel J DeAngelo, Richard M Stone
Blood|October 3, 2009
Screens, iron, and leukemiaRichard M Stone, Daniel J DeAngelo
Hematology/Oncology Clinics of North America|July 5, 2017
The Development of FLT3 Inhibitors in Acute Myeloid LeukemiaJacqueline S Garcia, Richard M Stone
Journal of Oncology Practice|August 11, 2017
Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice?Marlise R Luskin, Richard M Stone
Hematology/Oncology Clinics of North America|April 3, 2010
Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromesDavid P Steensma, Richard M Stone
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed diseaseL Andres Sirulnik, Richard M Stone
Blood Advances|January 28, 2025
Things (like AML salvage) go better with VEN(etoclax)Eric S Winer, Richard M Stone
Current Opinion in Oncology|January 16, 2002
The challenge of acute myeloid leukemia in older patientsMikkael A Sekeres, Richard M Stone
Therapeutic Advances in Hematology|July 20, 2019
Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approachesEric S Winer, Richard M Stone
Blood|July 23, 2011
Lenalidomide in AML: del(5q) or who?David P Steensma, Richard M Stone
Pageof 42